Literature DB >> 17894534

Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV--the oropharyngeal retention effect for four inhalation delivery systems.

Patricia K P Burnell1, Lars Asking, Lars Borgström, Steve C Nichols, Bo Olsson, David Prime, Ian Shrubb.   

Abstract

Magnetic resonance imaging (MRI) of the oropharyngeal region from 20 adult volunteers using four model inhalation devices (varying mouthpiece diameters, airflow resistances) and tidal breathing was carried out. Statistical analysis (convex hull method) selected 12 scans from 80 data sets representing the extremes of all dimensions in the population. Twelve physical mouth-throat models were made by stereolithography using the exact scan data. The aim was to produce models with varying dimensions to span the adult population, and to investigate if oropharyngeal dimensions affected throat retention for different delivery systems. In an in vitro analysis, the models were used to determine the retention effect of the oropharyngeal airspaces when drug aerosols were administered from four inhalation delivery systems: a pressurised metered dose inhaler (pMDI), two different dry powder inhalers (DPIs A and B), and a nebulizer. The aims of this work were to determine the key parameters governing mouth-throat retention and whether retention was dependent on the delivery system used. Characterizing the throat models by measuring 51 different dimensional variables enabled determination of the most influential variables for dose retention for each inhalation delivery system. Throat model retention was found to be dependent on the delivery system (pMDI approximately DPI(A) > DPI(B) > Neb.). The most influential variable was the total throat model volume. Throat models representing high, median, and low oropharyngeal filtration in healthy adults have been identified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894534     DOI: 10.1089/jam.2007.0566

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  7 in total

1.  The interaction between the oropharyngeal geometry and aerosols via pressurised metered dose inhalers.

Authors:  T Ehtezazi; I Saleem; I Shrubb; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2009-11-10       Impact factor: 4.200

Review 2.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

Review 3.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

Review 4.  Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.

Authors:  Juliet Rebello; Bill Brashier; Sharvari Shukla
Journal:  Daru       Date:  2022-01-30       Impact factor: 4.088

5.  Development of characteristic upper tracheobronchial airway models for testing pharmaceutical aerosol delivery.

Authors:  Ross L Walenga; Geng Tian; P Worth Longest
Journal:  J Biomech Eng       Date:  2013-09       Impact factor: 2.097

Review 6.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

7.  Determination of regional lung air volume distribution at mid-tidal breathing from computed tomography: a retrospective study of normal variability and reproducibility.

Authors:  John Fleming; Joy Conway; Caroline Majoral; Michael Bennett; Georges Caillibotte; Spyridon Montesantos; Ira Katz
Journal:  BMC Med Imaging       Date:  2014-07-25       Impact factor: 1.930

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.